Enavate Sciences Gp, LLC
In its 13F for Q2 2025 (holdings as of June 30, 2025, filed August 14, 2025), Enavate Sciences Gp, LLC reported 6 stock positions worth $176.5 million. Its top holding was Immunome (IMNM) at 25.1% of the portfolio, followed by Sionna Therapeutics (SION, 24.4%) and Zenas Biopharma (ZBIO, 20.6%). Its holdings were unchanged from Q1 2025.
- Most Recent 13F
- Q2 2026
- Location
- New York, NY
- CIK
- 0001953107
- Portfolio Value
- $176.5M (Q2 2025)
- SEC Filing
- 0001415889-25-021852 ↗ filed Aug 14, 2025
Holdings Value
Holdings 6 stocks · $176.5M
| IMNM Immunome Inc. | 25.12% | 4,768,583 | $44.3M | No change |
| SION Sionna Therapeutics Inc. | 24.35% | 2,478,030 | $43.0M | No change |
| ZBIO Zenas Biopharma Inc. | 20.65% | 3,761,359 | $36.4M | No change |
| UPB Upstream Bio Inc. | 15.30% | 2,459,703 | $27.0M | No change |
| CMPX Compass Therapeutics Inc. | 11.47% | 7,788,150 | $20.2M | No change |
| CAMP CAMP4 Therapeutics Corp. | 3.11% | 3,785,802 | $5.5M | No change |
Portfolio Sells Q1 2025 → Q2 2025
| None this quarter. | |||
Portfolio Buys Q1 2025 → Q2 2025
| None this quarter. | |||
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 7 | $345.4M | SION, ZBIO, IMNM, BBOT, CMPX |
| Q1 2026 | 7 | $351.5M | SION, IMNM, ZBIO, CMPX, BBOT |
| Q4 2025 | 7 | $506.8M | ZBIO, IMNM, SION, UPB, CMPX |
| Q3 2025 | 7 | $327.5M | ZBIO, SION, IMNM, UPB, BBOT |
| Q2 2025 | 6 | $176.5M | IMNM, SION, ZBIO, UPB, CMPX |
| Q1 2025 | 6 | $132.7M | IMNM, ZBIO, SION, CAMP, UPB |
| Q4 2024 | 5 | $139.2M | UPB, IMNM, ZBIO, CAMP, CMPX |